Tags

Type your tag names separated by a space and hit enter

Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS.
Mult Scler Relat Disord. 2020 Aug; 43:102158.MS

Abstract

Multiple sclerosis (MS) is a chronic, immune-mediated, inflammatory disease affecting the white and gray matter of the central nervous system. Several disease modifying therapies (DMTs) have been shown to significantly reduce relapse rates, slow disability worsening, and modify the overall disease course of MS. Decision-making when initiating a DMT should be shared between the patient and physician. Important factors such as prognostic indicators, safety, patient preferences, adherence, and convenience should also be considered. Treatment guidelines recommend switching a DMT when a patient experiences breakthrough disease activity, but also for patients who experience adverse events. Compared with injectable therapies, oral DMTs are often associated with increased treatment adherence and patient satisfaction, due to a less burdensome route of administration and greater tolerability. This review will summarize the available scientific evidence for injectable DMTs and the oral DMT teriflunomide, including considerations for both treatment-naïve patients initiating a DMT and patients switching from an injectable DMT.

Authors+Show Affiliations

Univ. Lille, INSERM U-S1172, CHU Lille, FHU Imminent, Lille 59037, France. Electronic address: patrick.vermersch@univ-lille.fr.St Michael's Hospital, Toronto, ON, Canada.Tampa Neurology Associates, South Tampa Multiple Sclerosis Center, South Tampa, FL, USA.Department of Neurology, Hospital Clinico San Carlos, Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid (UCM), IdISSC, Madrid, Spain.Department of Neurology, Multiple Sclerosis Center (MSC), Neurocenter of Southern Switzerland, Lugano, Switzerland.Phoenix Neurological Associates Ltd, Phoenix, AZ, USA; University of Arizona College of Medicine, Tucson, AZ, USA.Haukeland University Hospital, Bergen, Norway; University of Bergen, Bergen, Norway.Stony Brook University, Stony Brook, NY, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32470857

Citation

Vermersch, Patrick, et al. "Teriflunomide Vs Injectable Disease Modifying Therapies for Relapsing Forms of MS." Multiple Sclerosis and Related Disorders, vol. 43, 2020, p. 102158.
Vermersch P, Oh J, Cascione M, et al. Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS. Mult Scler Relat Disord. 2020;43:102158.
Vermersch, P., Oh, J., Cascione, M., Oreja-Guevara, C., Gobbi, C., Travis, L. H., Myhr, K. M., & Coyle, P. K. (2020). Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS. Multiple Sclerosis and Related Disorders, 43, 102158. https://doi.org/10.1016/j.msard.2020.102158
Vermersch P, et al. Teriflunomide Vs Injectable Disease Modifying Therapies for Relapsing Forms of MS. Mult Scler Relat Disord. 2020;43:102158. PubMed PMID: 32470857.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS. AU - Vermersch,Patrick, AU - Oh,Jiwon, AU - Cascione,Mark, AU - Oreja-Guevara,Celia, AU - Gobbi,Claudio, AU - Travis,Lori H, AU - Myhr,Kjell-Morten, AU - Coyle,Patricia K, Y1 - 2020/05/13/ PY - 2019/10/16/received PY - 2020/02/24/revised PY - 2020/04/26/accepted PY - 2020/5/30/pubmed PY - 2020/5/30/medline PY - 2020/5/30/entrez KW - Disease modifying therapies KW - Injectable DMTs KW - Multiple sclerosis KW - Switching KW - Teriflunomide SP - 102158 EP - 102158 JF - Multiple sclerosis and related disorders JO - Mult Scler Relat Disord VL - 43 N2 - Multiple sclerosis (MS) is a chronic, immune-mediated, inflammatory disease affecting the white and gray matter of the central nervous system. Several disease modifying therapies (DMTs) have been shown to significantly reduce relapse rates, slow disability worsening, and modify the overall disease course of MS. Decision-making when initiating a DMT should be shared between the patient and physician. Important factors such as prognostic indicators, safety, patient preferences, adherence, and convenience should also be considered. Treatment guidelines recommend switching a DMT when a patient experiences breakthrough disease activity, but also for patients who experience adverse events. Compared with injectable therapies, oral DMTs are often associated with increased treatment adherence and patient satisfaction, due to a less burdensome route of administration and greater tolerability. This review will summarize the available scientific evidence for injectable DMTs and the oral DMT teriflunomide, including considerations for both treatment-naïve patients initiating a DMT and patients switching from an injectable DMT. SN - 2211-0356 UR - https://www.unboundmedicine.com/medline/citation/32470857/Teriflunomide_vs_injectable_disease_modifying_therapies_for_relapsing_forms_of_MS L2 - https://linkinghub.elsevier.com/retrieve/pii/S2211-0348(20)30234-0 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.